Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azenta, Inc.AZTA · Entity 4724 | Director | February 05, 2026 | February 06, 2026 |
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Director · CEO | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azenta, Inc.
Report date February 05, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 9,703 |
Reported balance
After 2026-02-05 transaction · row 1
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 5,663 · Balance 9,703 F1: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of unrestricted shares under the Company's 2020 Equity Incentive Plan. No amount was paid upon grant of the shares.
Entrada Therapeutics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 517,290 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Tax withholding · Disposed 8,724 · Balance 517,290 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.97 to $7.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2022 Filed Dec 29, 2022 21:51 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 9,069 | $15.04 | $136,383.25 |
DisclosureSEC source: 0001689375-22-000050 · wf-form4_167235065224928.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,166 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 21:51 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 600 | $14.80 | $8,879.34 |
DisclosureSEC source: 0001689375-22-000050 · wf-form4_167235065224928.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,235 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 21:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,000 | $13.91 | $27,826.20 |
DisclosureSEC source: 0001689375-22-000047 · wf-form4_166984388092063.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,835 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.65 to $14.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2022 Filed Oct 27, 2022 22:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,000 | $21.66 | $43,325.00 |
DisclosureSEC source: 0001689375-22-000037 · wf-form4_166691078721508.xml · nonDerivative · entry 4 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,835 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $21.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,500 | $21.50 | $32,251.05 |
DisclosureSEC source: 0001689375-22-000037 · wf-form4_166691078721508.xml · nonDerivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,835 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 7,506 | $20.76 | $155,808.05 |
DisclosureSEC source: 0001689375-22-000037 · wf-form4_166691078721508.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,335 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $21.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 22:46 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,055 | $20.01 | $61,127.50 |
DisclosureSEC source: 0001689375-22-000037 · wf-form4_166691078721508.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,841 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.31 to $20.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 24, 2022 Filed Oct 24, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,241 | $19.65 | $24,380.19 |
DisclosureSEC source: 0001689375-22-000035 · wf-form4_166664578949593.xml · nonDerivative · entry 4 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,896 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.39 to $19.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 24, 2022 Filed Oct 24, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,101 | $18.90 | $20,808.79 |
DisclosureSEC source: 0001689375-22-000035 · wf-form4_166664578949593.xml · nonDerivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,137 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.30 to $19.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 21, 2022 Filed Oct 24, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,786 | $18.28 | $50,916.66 |
DisclosureSEC source: 0001689375-22-000035 · wf-form4_166664578949593.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,238 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 811 | $18.01 | $14,607.16 |
DisclosureSEC source: 0001689375-22-000035 · wf-form4_166664578949593.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,024 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 28, 2022 Filed Sep 28, 2022 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,085 | $15.23 | $46,996.58 |
DisclosureSEC source: 0001689375-22-000034 · wf-form4_166439953248663.xml · nonDerivative · entry 5 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,835 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2022 Filed Sep 28, 2022 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 966 | $15.82 | $15,285.98 |
DisclosureSEC source: 0001689375-22-000034 · wf-form4_166439953248663.xml · nonDerivative · entry 4 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,920 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.51 to $16.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 27, 2022 Filed Sep 28, 2022 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,453 | $15.04 | $51,933.81 |
DisclosureSEC source: 0001689375-22-000034 · wf-form4_166439953248663.xml · nonDerivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,886 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.51 to $15.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 288 | $16.30 | $4,695.21 |
DisclosureSEC source: 0001689375-22-000034 · wf-form4_166439953248663.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,339 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.12 to $16.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 21:12 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,795 | $15.22 | $42,530.12 |
DisclosureSEC source: 0001689375-22-000034 · wf-form4_166439953248663.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,627 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 23, 2022 Filed Sep 23, 2022 20:59 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,023 | $15.07 | $15,412.52 |
DisclosureSEC source: 0001689375-22-000031 · wf-form4_166396674271987.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,422 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 20:59 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,402 | $15.12 | $51,425.31 |
DisclosureSEC source: 0001689375-22-000031 · wf-form4_166396674271987.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,445 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:35 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 200 | $15.04 | $3,008.00 |
DisclosureSEC source: 0001689375-22-000028 · wf-form4_166361972573007.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,847 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.01 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:21 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 688 | $15.07 | $10,366.03 |
DisclosureSEC source: 0001689375-22-000022 · wf-form4_166301404769113.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:21 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,100 | $15.16 | $16,673.47 |
DisclosureSEC source: 0001689375-22-000022 · wf-form4_166301404769113.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,735 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:31 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 15,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-097872 · tm2225276-5_4seq1.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,835 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| August 31, 2022 Filed Aug 31, 2022 20:55 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 171 | $12.00 | $2,052.00 |
DisclosureSEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 5 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,710 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| August 30, 2022 Filed Aug 31, 2022 20:55 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 190 | $12.00 | $2,280.00 |
DisclosureSEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 4 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,881 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 20:55 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 25 | $14.00 | $350.00 |
DisclosureSEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 3 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,071 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 20:55 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 505 | $13.51 | $6,822.40 |
DisclosureSEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,096 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 20:55 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,109 | $12.56 | $13,930.70 |
DisclosureSEC source: 0001689375-22-000016 · wf-form4_166197928416013.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,601 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 20:03 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,000 | $12.00 | $24,000.00 |
DisclosureSEC source: 0001104659-22-084212 · tm2222095-2_4seq1.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,710 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:15 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 90,750 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001104659-22-077702 · tm2220515-1_4seq1.xml · derivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,750 Underlying: Common Stock · 90,750 shares Expires 2032-07-01 F1 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on July 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on July 1, 2026. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 20:02 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 4,000 | $12.00 | $48,000.00 |
DisclosureSEC source: 0001104659-22-075786 · tm2220048-1_4seq1.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,710 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:08 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 181,500 | $0.00 Strike: $11.57 | $0.00 |
DisclosureSEC source: 0001104659-22-030002 · tm228284d1_4seq1.xml · derivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,500 Underlying: Common stock · 181,500 shares Expires 2032-03-01 F3 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:08 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 30,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-030002 · tm228284d1_4seq1.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,710 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F2 · balance_after: Consists of (i) 172,467 shares of common stock (ii) 11,993 shares of restricted common stock issued upon early exercise of stock options, and (iii) 30,250 RSUs reported in this transaction. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 23:01 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001104659-22-004980 · tm223204-1_4seq1.xml · derivative · entry 2 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,989 Underlying: Common Stock · 10,000 shares Expires 2029-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 31, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 23:01 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 10,000 | $1.74 | $17,400.00 |
DisclosureSEC source: 0001104659-22-004980 · tm223204-1_4seq1.xml · nonDerivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Consists of (i) 170,067 shares of common stock and (ii) 14,393 shares of restricted common stock issued upon early exercise of stock options. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 22:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 184,821 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001104659-21-132475 · tm2131250-20_4seq1.xml · derivative · entry 1 Doshi Dipal · CIK 0001613084 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,821 Underlying: Common Stock · 184,821 shares Expires 2031-10-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments commencing on October 28, 2021 (the "Vesting Start Date"), such that the option shares shall be fully vested on the four-year anniversary of the Vesting Start Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.